(NASDAQ: MRNA) Moderna's forecast annual revenue growth rate of 12.63% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Moderna's revenue in 2026 is $2,225,000,000.On average, 27 Wall Street analysts forecast MRNA's revenue for 2026 to be $843,567,586,634, with the lowest MRNA revenue forecast at $753,497,105,841, and the highest MRNA revenue forecast at $918,956,975,844. On average, 26 Wall Street analysts forecast MRNA's revenue for 2027 to be $1,011,804,960,450, with the lowest MRNA revenue forecast at $753,100,319,582, and the highest MRNA revenue forecast at $2,016,864,554,497.
In 2028, MRNA is forecast to generate $1,280,826,044,052 in revenue, with the lowest revenue forecast at $852,296,884,332 and the highest revenue forecast at $3,071,919,217,178.